<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28786530</article-id><article-id pub-id-type="pmc">5846888</article-id><article-id pub-id-type="doi">10.1111/dom.13079</article-id><article-id pub-id-type="publisher-id">DOM13079</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double&#x02010;blind, placebo&#x02010;controlled, parallel&#x02010;group comparative study</article-title><alt-title alt-title-type="left-running-head">Kadowaki et al.</alt-title></title-group><contrib-group><contrib id="dom13079-cr-0001" contrib-type="author"><name><surname>Kadowaki</surname><given-names>Takashi</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom13079-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13079-cr-0002" contrib-type="author"><name><surname>Inagaki</surname><given-names>Nobuya</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom13079-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13079-cr-0003" contrib-type="author"><name><surname>Kondo</surname><given-names>Kazuoki</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom13079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13079-cr-0004" contrib-type="author"><name><surname>Nishimura</surname><given-names>Kenichi</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="dom13079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13079-cr-0005" contrib-type="author"><name><surname>Kaneko</surname><given-names>Genki</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="dom13079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13079-cr-0006" contrib-type="author"><name><surname>Maruyama</surname><given-names>Nobuko</given-names></name><degrees>Bachelor of Pharmacology</degrees><xref ref-type="aff" rid="dom13079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13079-cr-0007" contrib-type="author"><name><surname>Nakanishi</surname><given-names>Nobuhiro</given-names></name><degrees>MMath</degrees><xref ref-type="aff" rid="dom13079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13079-cr-0008" contrib-type="author"><name><surname>Gouda</surname><given-names>Maki</given-names></name><degrees>B.Sc.(Agr.)</degrees><xref ref-type="aff" rid="dom13079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13079-cr-0009" contrib-type="author"><name><surname>Iijima</surname><given-names>Hiroaki</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13079-cr-0010" contrib-type="author" corresp="yes"><name><surname>Watanabe</surname><given-names>Yumi</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8875-7598</contrib-id><address><email>watanabe.yumi@mf.mt-pharma.co.jp</email></address><xref ref-type="aff" rid="dom13079-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="dom13079-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Diabetes and Metabolic Diseases, Graduate School of Medicine</named-content>
<institution>The University of Tokyo</institution>
<named-content content-type="city">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="dom13079-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Diabetes, Endocrinology, and Nutrition, Graduate School of Medicine</named-content>
<institution>Kyoto University</institution>
<named-content content-type="city">Kyoto</named-content>
<country country="JP">Japan</country>
</aff><aff id="dom13079-aff-0003" content-type="private-address">
<label><sup>3</sup></label>
<named-content content-type="organisation-division"> Ikuyaku. Integrated Value Development Division</named-content>
<institution>Mitsubishi Tanabe Pharma Corporation</institution>
<named-content content-type="city">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Yumi Watanabe, Medical Science Department, Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, 17&#x02013;10 Nihonbashi&#x02010;Koamicho, Chuo&#x02010;ku, Tokyo 103&#x02010;8405, Japan. Email: <email>watanabe.yumi@mf.mt-pharma.co.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2018</year></pub-date><volume>20</volume><issue>2</issue><issue-id pub-id-type="doi">10.1111/dom.2018.20.issue-2</issue-id><fpage>453</fpage><lpage>457</lpage><history><date date-type="received"><day>22</day><month>5</month><year>2017</year></date><date date-type="rev-recd"><day>26</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>03</day><month>8</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-20-453.pdf"/><abstract><p>Dipeptidyl peptidase&#x02010;4 (DPP&#x02010;4) inhibitors and sodium glucose co&#x02010;transporter 2 (SGLT2) inhibitors are frequently used in combination for the treatment of type 2 diabetes mellitus (T2DM). We examined the efficacy and safety of teneligliptin (a DPP&#x02010;4 inhibitor) added to canagliflozin (an SGLT2 inhibitor) monotherapy in Japanese patients with poorly controlled T2DM as part of the development of a fixed&#x02010;dose combination of teneligliptin and canagliflozin.</p><p>Japanese patients treated with canagliflozin (100 mg) for &#x02265;12 weeks were randomized to receive add&#x02010;on teneligliptin (20 mg; C + T group) or placebo (C + P group) for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to Week 24. The between&#x02010;group differences in reductions from baseline to Week 24 were significantly greater in the C + T group for HbA1c (&#x02212;0.94%; <italic>P</italic> &#x0003c; .001). The incidence of adverse events was similar in both groups (55.8% and 49.4% in the C + T and C + P groups, respectively). No episodes of hypoglycaemia were reported. Teneligliptin added to ongoing canagliflozin monotherapy improved glycaemic control and was well tolerated in Japanese patients with inadequately controlled T2DM.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom13079-kwd-0001">canagliflozin</kwd><kwd id="dom13079-kwd-0002">dipeptidyl peptidase&#x02010;4 inhibitor</kwd><kwd id="dom13079-kwd-0003">sodium glucose co&#x02010;transporter 2 inhibitor</kwd><kwd id="dom13079-kwd-0004">teneligliptin</kwd><kwd id="dom13079-kwd-0005">type 2 diabetes mellitus</kwd></kwd-group><funding-group><award-group><funding-source>Mitsubishi Tanabe Pharma Corporation</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="5"/><word-count count="3559"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom13079</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.2.2 mode:remove_FC converted:15.02.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom13079-cit-0001">
<string-name>
<surname>Kadowaki</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Inagaki</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>K.</given-names>
</string-name> et al. <article-title>Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double&#x02010;blind, placebo&#x02010;controlled, parallel&#x02010;group comparative study</article-title>. <source>Diabetes Obes Metab.</source>
<year>2018</year>;<volume>20</volume>:<fpage>453</fpage>&#x02013;<lpage>457</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.13079">https://doi.org/10.1111/dom.13079</ext-link>
<pub-id pub-id-type="pmid">28786530</pub-id></mixed-citation>
</p><fn-group id="dom13079-ntgp-0001"><fn id="dom13079-note-0001"><p>
<bold>Funding information</bold> This study was funded by Mitsubishi Tanabe Pharma Corporation.</p></fn></fn-group></notes></front><body><sec id="dom13079-sec-0001"><label>1</label><title>INTRODUCTION</title><p>By inhibiting the degradation of glucagon&#x02010;like peptide&#x02010;1, dipeptidyl peptidase&#x02010;4 (DPP&#x02010;4) inhibitors promote insulin secretion and suppress glucagon secretion. Because the mode of action is dependent on the glucose concentration, DPP&#x02010;4 inhibitors have a low risk of causing hypoglycaemia.<xref rid="dom13079-bib-0001" ref-type="ref">1</xref> Sodium glucose co&#x02010;transporter 2 (SGLT2) inhibitors reduce urinary glucose reabsorption by inhibiting SGLT2, lower plasma glucose in an insulin&#x02010;independent manner and help to alleviate glucose toxicity. They are also expected to improve insulin resistance by alleviating glucose toxicity and decreasing body weight.<xref rid="dom13079-bib-0002" ref-type="ref">2</xref>, <xref rid="dom13079-bib-0003" ref-type="ref">3</xref> The independent mechanisms of action of these drugs and the low risk of hypoglycaemia provide support for combination therapy as a therapeutic option. Indeed, prior studies have demonstrated that combination therapy with an SGLT2 inhibitor and a DPP&#x02010;4 inhibitor was effective and well tolerated.<xref rid="dom13079-bib-0004" ref-type="ref">4</xref>, <xref rid="dom13079-bib-0005" ref-type="ref">5</xref>, <xref rid="dom13079-bib-0006" ref-type="ref">6</xref>, <xref rid="dom13079-bib-0007" ref-type="ref">7</xref>, <xref rid="dom13079-bib-0008" ref-type="ref">8</xref>
</p><p>Consequently, fixed&#x02010;dose combinations of a DPP&#x02010;4 inhibitor and an SGLT2 inhibitor are anticipated, and 2 fixed&#x02010;dose combination drugs of a DPP&#x02010;4 inhibitor and an SGLT2 inhibitor, linagliptin/empagliflozin and saxagliptin/dapagliflozin, have been launched in the USA and Europe, respectively.<xref rid="dom13079-bib-0008" ref-type="ref">8</xref>, <xref rid="dom13079-bib-0009" ref-type="ref">9</xref>, <xref rid="dom13079-bib-0010" ref-type="ref">10</xref> No fixed&#x02010;dose combinations of a DPP&#x02010;4 inhibitor and an SGLT2 inhibitor have been approved in Japan.</p><p>In this context, the development of a fixed&#x02010;dose combination of teneligliptin, a DPP&#x02010;4 inhibitor, and canagliflozin, an SGLT2 inhibitor, has proceeded. A study examining the efficacy and safety of adding canagliflozin to ongoing teneligliptin therapy in Japanese patients has also been conducted (NCT02354235, NCT02220907), and the results have been reported previously.<xref rid="dom13079-bib-0011" ref-type="ref">11</xref>, <xref rid="dom13079-bib-0012" ref-type="ref">12</xref> In this study, we examined the efficacy of teneligliptin added to canagliflozin monotherapy in Japanese patients with poorly controlled T2DM as part of the development programme. This is the first clinical trial evaluating the efficacy and safety of adding a DPP&#x02010;4 inhibitor to ongoing SGLT2 inhibitor treatment in Japanese T2DM patients. Therefore, this trial provides important information because there are differences in the pathology of T2DM between Japanese and Caucasian patients.<xref rid="dom13079-bib-0013" ref-type="ref">13</xref>
</p></sec><sec id="dom13079-sec-0002"><label>2</label><title>METHODS</title><p>Details of the patient inclusion/exclusion criteria, secondary efficacy endpoints and statistical analyses are provided in <xref rid="dom13079-supitem-0001" ref-type="supplementary-material">Appendix S1</xref> (Methods). In brief, Japanese patients with T2DM and inadequate glycaemic control despite canagliflozin monotherapy in conjunction with diet and exercise therapy were eligible, provided they had undergone canagliflozin monotherapy for &#x02265;8 weeks before the run&#x02010;in period.</p><sec id="dom13079-sec-0003"><label>2.1</label><title>Ethics</title><p>This trial complied with the Declaration of Helsinki, the Japanese Law for Ensuring the Quality, Efficacy, and Safety of Drugs and Medical Devices, Good Clinical Practice, and the approved study protocol. The procedures were approved by institutional review boards at all participating institutions, which are listed in <xref rid="dom13079-supitem-0001" ref-type="supplementary-material">Appendix S1</xref>. The trial was registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> (NCT02354222).</p></sec><sec id="dom13079-sec-0004"><label>2.2</label><title>Study design and treatments</title><p>The study comprised a 4&#x02010;week run&#x02010;in period, a 24&#x02010;week double&#x02010;blind treatment period, and a 2&#x02010;week post&#x02010;treatment observation period (Figure <xref rid="dom13079-supitem-0002" ref-type="supplementary-material">S1</xref>). All patients received canagliflozin at a dose of 100 mg (the approved dose in Japan) once daily before breakfast during the run&#x02010;in period, treatment period and post&#x02010;treatment observation period. At the start of the treatment period, patients were randomized in a 1:1 manner to receive placebo (C + P group) or teneligliptin (C + T group) at a dose of 20 mg once daily before breakfast. Randomization was performed using the permuted block method. Diet and exercise therapy was to continue unchanged throughout the trial.</p></sec><sec id="dom13079-sec-0005"><label>2.3</label><title>Primary efficacy and safety endpoints</title><p>The primary efficacy endpoint was the change in HbA1c from baseline to the end of the treatment period. The safety of C + T and C + P was assessed in terms of adverse events (AEs), hypoglycaemia, laboratory variables (haematology, blood biochemistry and urinalysis), electrocardiography and vital signs. AEs were evaluated in terms of their seriousness and relationship to the study drugs. AEs and drug&#x02010;related AEs were classified according to the System Organ Class and Preferred Term using the MedDRA version 18.1J.</p></sec></sec><sec id="dom13079-sec-0006"><label>3</label><title>RESULTS</title><sec id="dom13079-sec-0007"><label>3.1</label><title>Patient disposition and baseline characteristics</title><p>A total of 213 patients were initially enrolled, of whom 59 discontinued before the treatment period (Figure <xref rid="dom13079-supitem-0003" ref-type="supplementary-material">S2</xref>); therefore, 154 patients were randomized, with 77 patients per group. Patient characteristics are shown in <xref rid="dom13079-supitem-0001" ref-type="supplementary-material">Table S1</xref>, <xref rid="dom13079-supitem-0001" ref-type="supplementary-material">Appendix S1</xref>.</p></sec><sec id="dom13079-sec-0008"><label>3.2</label><title>Efficacy variables</title><p>The primary endpoint, the LS mean &#x000b1; SE (baseline value as covariate) change in HbA1c from baseline to Week 24 (LOCF) was 0.00% &#x000b1; 0.08% and &#x02212;0.94% &#x000b1; 0.08% in the C + P and C + T groups, respectively, with a significant between&#x02010;group difference of &#x02212;0.94% &#x000b1; 0.11% (<italic>P</italic> &#x0003c; .001, two&#x02010;sided ANCOVA as specified in the protocol) (<xref rid="dom13079-supitem-0001" ref-type="supplementary-material">Table S2</xref>, <xref rid="dom13079-supitem-0001" ref-type="supplementary-material">Appendix S1</xref>). As illustrated in Figure <xref rid="dom13079-fig-0001" ref-type="fig">1</xref>, HbA1c started to decrease within 4 weeks of treatment in the C + T group and continued to decrease through to Week 12, and the reduction was sustained until the end of treatment. By contrast, HbA1c remained broadly unchanged in the C + P group. Significantly greater proportions of patients in the C + T group than in the C + P group achieved HbA1c &#x0003c;7.0% (50.00% vs 8.11%, respectively; <italic>P</italic> &#x0003c; .001) or &#x0003c;8.0% (75.76% vs 18.42%, respectively; <italic>P</italic> &#x0003c; .001, 2&#x02010;sided Fisher's exact test as specified in the protocol) at Week 24 (LOCF).</p><fig fig-type="Figure" xml:lang="en" id="dom13079-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Changes in HbA1c from baseline to each visit during the 24&#x02010;week treatment period, and at the last observation carried forward. Values are expressed as the least squares mean &#x000b1; standard error. The least squares mean was determined by analysis of covariance with treatment group as a fixed factor and the baseline value as a covariate. *<italic>P</italic> &#x0003c; .001 for the C + T group vs C + P group at all time points. C + P, canagliflozin plus placebo; C + T, canagliflozin plus teneligliptin; HbA1c, glycated haemoglobin; LOCF, last observation carried forward; LS mean, least squares mean</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-20-453-g001"/></fig><p>
<xref rid="dom13079-supitem-0001" ref-type="supplementary-material">Table S2</xref> (<xref rid="dom13079-supitem-0001" ref-type="supplementary-material">Appendix S1</xref>) shows the changes in other efficacy endpoints from baseline to Week 24 (LOCF). Supporting the change in HbA1c, the reduction in FPG was significantly greater in the C + T group, with a between&#x02010;group difference of &#x02212;15.6 &#x000b1; 3.9 mg/dL (LS mean &#x000b1; SE, <italic>P</italic> &#x0003c; .001, two&#x02010;sided ANCOVA [baseline value as covariate] as specified in the protocol). The absolute and percent changes in body weight were 0.11 &#x000b1; 0.20 kg and 0.09% &#x000b1; 0.29%, respectively, in the C + T group vs &#x02212;0.98 &#x000b1; 0.20 kg and &#x02212;1.34% &#x000b1; 0.29%, respectively, in the C + P group. The between&#x02010;group differences in changes in body weight were 1.09 &#x000b1; 0.29 kg and 1.43% &#x000b1; 0.41% (both <italic>P</italic> &#x0003c; .001), respectively. Additional efficacy results and the results of a mixed&#x02010;meal tolerance test are included in <xref rid="dom13079-supitem-0001" ref-type="supplementary-material">Appendix S1</xref> (Results).</p></sec><sec id="dom13079-sec-0009"><label>3.3</label><title>Safety</title><p>Table <xref rid="dom13079-tbl-0001" ref-type="table-wrap">1</xref> shows the incidence of AEs, including AEs of special interest in both groups. AEs and drug&#x02010;related AEs occurred in 49.4% and 14.3% of patients, respectively, in the C + P group and in 55.8% and 6.5% of patients, respectively, in the C + T group. Serious AEs occurred in 2.6% and 1.3% of patients in the C + P and C + T groups, respectively. There were no serious drug&#x02010;related AEs in either group. AEs led to discontinuation and drug&#x02010;related AEs led to discontinuation in 3.9% and 1.3% of patients, respectively, in the C + P group. There were no AEs leading to treatment discontinuation in the C + T group. In terms of AEs of special interest, there were no episodes of hypoglycaemia in either group. Gastrointestinal disorders (11.7% vs 7.8%) and skin and subcutaneous tissue disorders (10.4% vs 5.2%) were more common in the C + T group than in the C + P group. Malignant neoplasms occurred in 2.6% of patients in the C + P group and in no patients in the C + T group. Other AEs of clinical relevance occurred in &#x02264;2 patients in each group.</p><table-wrap id="dom13079-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Adverse events</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="middle"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="center" valign="middle" colspan="1"/><th colspan="2" align="center" valign="middle" rowspan="1">C + P</th><th colspan="2" align="center" valign="middle" rowspan="1">C + T</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="middle" rowspan="1" colspan="1">n</th><th align="left" valign="middle" rowspan="1" colspan="1">(%)</th><th align="left" valign="middle" rowspan="1" colspan="1">n</th><th align="left" valign="middle" rowspan="1" colspan="1">(%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">AEs</td><td align="left" valign="top" rowspan="1" colspan="1">38</td><td align="left" valign="top" rowspan="1" colspan="1">(49.4)</td><td align="left" valign="top" rowspan="1" colspan="1">43</td><td align="left" valign="top" rowspan="1" colspan="1">(55.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drug&#x02010;related AEs</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">(14.3)</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">(6.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Serious AEs</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">(2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">(1.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Serious drug&#x02010;related AEs</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AEs leading to discontinuation</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">(3.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drug&#x02010;related AEs leading to discontinuation</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">(1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AEs of special interest</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hypoglycaemia</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Osmotic diuresis</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">(1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">(1.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Volume depletion</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">(1.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Vulvovaginal candidiasis</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">(5.3)<xref ref-type="fn" rid="dom13079-note-0003">a</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Urinary tract infection</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">(1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Blood ketone bodies increased</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">(2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">(1.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hepatic function impairment</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">(2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">(2.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Skin and subcutaneous tissue disorders</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">(5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">(10.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cardiovascular&#x02010;related events</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">(1.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Malignant neoplasm</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">(2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Gastrointestinal disorders</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">(7.8)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">(11.7)</td></tr></tbody></table><table-wrap-foot><fn id="dom13079-note-0002"><p>Abbreviations: C + P, canagliflozin plus placebo; C + T, canagliflozin plus teneligliptin; AE, adverse event.</p></fn><fn id="dom13079-note-0003"><label>a</label><p>In females only (n = 19).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="dom13079-sec-0010"><label>4</label><title>DISCUSSION</title><p>This randomized, placebo&#x02010;controlled, double&#x02010;blind, multicentre trial examined the efficacy and safety of teneligliptin or placebo added to canagliflozin therapy for 24 weeks in Japanese patients with inadequately controlled T2DM. Teneligliptin was associated with significant improvements in glycaemic control, including HbA1c, FPG and postprandial plasma glucose, compared with placebo. Moreover, greater proportions of patients in the C + T group achieved HbA1c &#x0003c;7.0% or &#x0003c;8.0%. These improvements were consistent with those observed in earlier clinical trials in which teneligliptin was added to oral hypoglycaemic drugs other than SGLT2 inhibitors.<xref rid="dom13079-bib-0014" ref-type="ref">14</xref>, <xref rid="dom13079-bib-0015" ref-type="ref">15</xref>, <xref rid="dom13079-bib-0016" ref-type="ref">16</xref> In fasting conditions, the fasting proinsulin/C&#x02010;peptide ratio was reduced and HOMA2&#x02010;%B was increased in the C + T group compared with the C + P group. In addition, in mixed&#x02010;meal tolerance tests, there were reductions in the changes from baseline in postprandial plasma glucose, as well as increases in the change from baseline in C&#x02010;peptide AUC<sub>0&#x02010;2h</sub> and the C&#x02010;peptide AUC<sub>0&#x02010;2hours</sub>/plasma glucose AUC<sub>0&#x02010;2hours</sub> in the C + T group compared with the C + P group.</p><p>These findings seem reasonable considering the mechanism of action of DPP&#x02010;4 inhibitors, which promote insulin secretion in a glucose concentration&#x02010;dependent manner.<xref rid="dom13079-bib-0001" ref-type="ref">1</xref> Taken together, these results support our hypothesis that teneligliptin added to ongoing canagliflozin therapy is beneficial in terms of improving glycaemic control in patients with inadequately controlled T2DM, because of their complementary but independent mechanisms of action.</p><p>Additionally, the use of canagliflozin and teneligliptin in combination is considered to have the following benefits. First, the attenuation of &#x003b2;&#x02010;cell burden by the SGLT2 inhibitor may lead to enhanced incretin&#x02010;stimulated insulin secretion. Second, because canagliflozin increases total GLP&#x02010;1 after meals,<xref rid="dom13079-bib-0017" ref-type="ref">17</xref> teneligliptin add&#x02010;on therapy may increase the level of active GLP&#x02010;1.</p><p>In this trial, the change in body weight from baseline to Week 24 was &#x02212;0.98 kg in the C + P group and 0.11 kg in the C + T group. The change in urinary glucose/creatinine ratio from baseline was lower in the C + T group compared with the C + P group, probably because of the glucose&#x02010;lowering effect of teneligliptin. This result suggests that calorie loss through glucose excretion was lower in the C + T group than in the C + P group throughout the treatment period. Furthermore, some meta&#x02010;analyses and clinical trials of teneligliptin have reported that DPP&#x02010;4 inhibitors negligibly increase body weight, probably as a result of enhanced insulin&#x02010;stimulated glucose uptake.<xref rid="dom13079-bib-0015" ref-type="ref">15</xref>, <xref rid="dom13079-bib-0016" ref-type="ref">16</xref>, <xref rid="dom13079-bib-0018" ref-type="ref">18</xref>, <xref rid="dom13079-bib-0019" ref-type="ref">19</xref>, <xref rid="dom13079-bib-0020" ref-type="ref">20</xref>
</p><p>The present trial also examined the safety of teneligliptin added to ongoing canagliflozin therapy. Of note, there were no serious drug&#x02010;related AEs or deaths. Moreover, no episodes of hypoglycaemia were detected. AEs related to osmotic diuresis, volume depletion, increased serum ketone bodies, hepatic function impairment, skin disorders, cardiovascular disorders and gastrointestinal disorders were observed in the C + T group. Although skin disorders and gastrointestinal disorders were slightly more frequent in the C + T group, only one skin disorder (eczema) and one gastrointestinal disorder (constipation) were considered to be drug&#x02010;related in the C + T group. These classes of AEs have already been reported for teneligliptin or canagliflozin, and there were no additional safety concerns. Overall, these findings suggest that teneligliptin added to canagliflozin therapy is likely to be well tolerated in clinical practice.</p><p>We previously reported that canagliflozin added to teneligliptin monotherapy in Japanese patients with poorly controlled T2DM was effective and well tolerated.<xref rid="dom13079-bib-0011" ref-type="ref">11</xref>, <xref rid="dom13079-bib-0012" ref-type="ref">12</xref> Taken together with the results of the present trial, this suggests that the fixed&#x02010;dose combination of teneligliptin and canagliflozin may be a beneficial treatment option.</p><p>Some limitations of this study warrant mention. In particular, we enrolled only Japanese patients. However, data on the use of this drug combination in Japanese patients are important, particularly when we consider the differences in pathophysiology between Japanese and non&#x02010;Japanese patients.<xref rid="dom13079-bib-0013" ref-type="ref">13</xref> Longer studies may be needed to verify the current findings obtained over 24 weeks.</p><p>In conclusion, this trial showed that teneligliptin added to ongoing canagliflozin therapy was effective in terms of improving glycaemic control and was well tolerated in Japanese patients with inadequately controlled T2DM.</p></sec><sec id="dom13079-sec-0014"><title>ORCID</title><p>
<italic>Yumi Watanabe</italic>&#x02009;
<ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-8875-7598">http://orcid.org/0000-0002-8875-7598</ext-link>
</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom13079-supitem-0001"><caption><p>
<bold>Appendix S1.</bold> Supplementary Methods. Patients, other efficacy endpoints<bold>,</bold> mixed&#x02010;meal tolerance test, sample size calculation, and statistical analyses.</p><p>Supplementary Results. Patient disposition and baseline characteristics, other efficacy endpoints, and mixed&#x02010;meal tolerance test.</p><p>
<bold>Table S1.</bold> Patient characteristics.</p><p>
<bold>Table S2.</bold> Effects of teneligliptin and placebo on primary and secondary efficacy endpoints.</p><p>
<bold>Table S3.</bold> Exclusion criteria.</p><p>
<bold>Table S4.</bold> Meal tolerance test&#x02010;related variables.</p><p>
<bold>Table S5.</bold> Change from baseline in blood glucose, C&#x02010;peptide and glucagon in the meal tolerance test at Week 24.</p></caption><media xlink:href="DOM-20-453-s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom13079-supitem-0002"><caption><p>
<bold>Figure S1.</bold> Study design.</p></caption><media xlink:href="DOM-20-453-s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom13079-supitem-0003"><caption><p>
<bold>Figure S2.</bold> Patient disposition and reasons for discontinuation.</p></caption><media xlink:href="DOM-20-453-s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom13079-supitem-0004"><caption><p>
<bold>Figure S3.</bold> Changes in urinary glucose/creatinine ratio (A) and total serum ketone bodies (B) from baseline to each visit in the 24&#x02010;week treatment period.</p></caption><media xlink:href="DOM-20-453-s004.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom13079-supitem-0005"><caption><p>
<bold>Figure S4.</bold> Effects of teneligliptin or placebo on variables determined in the mixed&#x02010;meal tolerance test.</p></caption><media xlink:href="DOM-20-453-s005.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom13079-sec-0011"><title>ACKNOWLEDGMENTS</title><p>The authors thank Nicholas D. Smith, PhD, of Edanz Medical Writing for providing medical writing services, which were funded by Mitsubishi Tanabe Pharma Corporation.</p><sec id="dom13079-sec-0012" sec-type="COI-statement"><title>Conflict of interest</title><p>T. K. has received consulting fees and/or speakers' bureau fees from Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K. and Nippon Boehringer Ingelheim Co., Ltd.; has received research support from Daiichi Sankyo Co., Ltd. and Takeda Pharmaceutical Co., Ltd.; has received scholarship grants from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Novo Nordisk Pharma Ltd., Sanofi K.K. and Ono Pharmaceutical Co., Ltd.; and teaches courses endowed by MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Kowa Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. N. I. has received consulting fees and/or speakers' bureau fees from Astellas Pharma Inc., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Sanofi K.K. and Takeda Pharmaceutical Co., Ltd.; has received research support from Eli Lilly Japan K.K., MSD K.K. and Mitsubishi Tanabe Pharma Corporation; and has received scholarship grants from Astellas Pharma Inc., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Japan Diabetes Foundation, Japan Tobacco Inc., Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. K. K., K. N., G. K., N. M., N. N., M. G., H. I. and Y. W. are employees of Mitsubishi Tanabe Pharma Corporation.</p></sec><sec id="dom13079-sec-0013"><title>Author contributions</title><p>T. K., N. I. and K. K. supervised the design and protocol of the study and contributed to the interpretation and discussion of the results as medical advisors for this study. K. N., G. K. and N. M. contributed to the study design, and collected the data. N. N. contributed to the data processing and statistical analysis. M. G., H. I. and Y. W. contributed to the writing of the manuscript. All authors contributed to the discussion of data, reviewed the manuscript and approved the final version of the manuscript.</p></sec></ack><ref-list id="dom13079-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="dom13079-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom13079-cit-0002">
<string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>. <article-title>Incretin therapies: highlighting common features and differences in the modes of action of glucagon&#x02010;like peptide&#x02010;1 receptor agonists and dipeptidyl peptidase&#x02010;4 inhibitors</article-title>. <source>Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>203</fpage>&#x02013;<lpage>216</lpage>.<pub-id pub-id-type="pmid">26489970</pub-id></mixed-citation></ref><ref id="dom13079-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom13079-cit-0003">
<string-name>
<surname>Abdul&#x02010;Ghani</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Norton</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Defronzo</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Role of sodium&#x02010;glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes</article-title>. <source>Endocr Rev</source>. <year>2011</year>;<volume>32</volume>:<fpage>515</fpage>&#x02013;<lpage>531</lpage>.<pub-id pub-id-type="pmid">21606218</pub-id></mixed-citation></ref><ref id="dom13079-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom13079-cit-0004">
<string-name>
<surname>Seufert</surname>
<given-names>J</given-names>
</string-name>. <article-title>SGLT2 inhibitors &#x02013; an insulin&#x02010;independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin</article-title>. <source>Diabetes Metab Syndr Obes</source>. <year>2015</year>;<volume>8</volume>:<fpage>543</fpage>&#x02013;<lpage>554</lpage>.<pub-id pub-id-type="pmid">26609242</pub-id></mixed-citation></ref><ref id="dom13079-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom13079-cit-0005">
<string-name>
<surname>Inagaki</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yoshinari</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kuki</surname>
<given-names>H</given-names>
</string-name>. <article-title>Efficacy and safety of canagliflozin alone or as add&#x02010;on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52&#x02010;week open&#x02010;label study</article-title>. <source>J Diabetes Investig</source>. <year>2015</year>;<volume>6</volume>:<fpage>210</fpage>&#x02013;<lpage>218</lpage>.</mixed-citation></ref><ref id="dom13079-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom13079-cit-0006">
<string-name>
<surname>Araki</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tanizawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Long&#x02010;term treatment with empagliflozin as add&#x02010;on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus</article-title>. <source>Diabetes Obes Metab</source>. <year>2015</year>;<volume>17</volume>:<fpage>665</fpage>&#x02013;<lpage>674</lpage>.<pub-id pub-id-type="pmid">25772548</pub-id></mixed-citation></ref><ref id="dom13079-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom13079-cit-0007">
<string-name>
<surname>Kaku</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Maegawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tanizawa</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open&#x02010;label study</article-title>. <source>Diabetes Ther</source>. <year>2014</year>;<volume>5</volume>:<fpage>415</fpage>&#x02013;<lpage>433</lpage>.<pub-id pub-id-type="pmid">25341477</pub-id></mixed-citation></ref><ref id="dom13079-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom13079-cit-0008">
<string-name>
<surname>Matthaei</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aggarwal</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Hernandez</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>One&#x02010;year efficacy and safety of saxagliptin add&#x02010;on in patients receiving dapagliflozin and metformin</article-title>. <source>Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>1128</fpage>&#x02013;<lpage>1133</lpage>.<pub-id pub-id-type="pmid">27403645</pub-id></mixed-citation></ref><ref id="dom13079-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom13079-cit-0009">
<string-name>
<surname>Scheen</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>DPP&#x02010;4 inhibitor plus SGLT&#x02010;2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects</article-title>. <source>Expert Opin Drug Metab Toxicol</source>. <year>2016</year>;<volume>12</volume>:<fpage>1407</fpage>&#x02013;<lpage>1417</lpage>.<pub-id pub-id-type="pmid">27435042</pub-id></mixed-citation></ref><ref id="dom13079-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom13079-cit-0010">
<string-name>
<surname>Raedler</surname>
<given-names>LA</given-names>
</string-name>. <article-title>Glyxambi (empagliflozin/linagliptin): a dual&#x02010;acting oral medication approved for the treatment of patients with type 2 diabetes</article-title>. <source>Am Health Drug Benefits</source>. <year>2015</year>;<volume>8</volume>:<fpage>171</fpage>&#x02013;<lpage>175</lpage>.<pub-id pub-id-type="pmid">26629285</pub-id></mixed-citation></ref><ref id="dom13079-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom13079-cit-0011">
<string-name>
<surname>Garnock&#x02010;Jones</surname>
<given-names>KP</given-names>
</string-name>. <article-title>Saxagliptin/Dapagliflozin: a review in type 2 diabetes mellitus</article-title>. <source>Drugs</source>. <year>2017</year>;<volume>77</volume>:<fpage>319</fpage>&#x02013;<lpage>330</lpage>.<pub-id pub-id-type="pmid">28176222</pub-id></mixed-citation></ref><ref id="dom13079-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom13079-cit-0012">
<string-name>
<surname>Kadowaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Inagaki</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Efficacy and safety of canagliflozin as add&#x02010;on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24&#x02010;week, randomised, double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>Diabetes Obes Metab</source>. <year>2017</year>;<volume>19</volume>:<fpage>874</fpage>&#x02013;<lpage>882</lpage>.<pub-id pub-id-type="pmid">28177187</pub-id></mixed-citation></ref><ref id="dom13079-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom13079-cit-0013">
<string-name>
<surname>Kadowaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Inagaki</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Long&#x02010;term safety and efficacy of canagliflozin as add&#x02010;on therapy to teneligliptin in Japanese patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2018</year>;<volume>20</volume>:<fpage>77</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">28608617</pub-id></mixed-citation></ref><ref id="dom13079-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom13079-cit-0014">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kuwata</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yabe</surname>
<given-names>D</given-names>
</string-name>. <article-title>Incretin&#x02010;based drugs for type 2 diabetes: focus on east Asian perspectives</article-title>. <source>J Diabetes Investig</source>. <year>2016</year>;<volume>7</volume>(<issue>suppl 1</issue>):<fpage>102</fpage>&#x02013;<lpage>109</lpage>.</mixed-citation></ref><ref id="dom13079-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom13079-cit-0015">
<string-name>
<surname>Kadowaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>K</given-names>
</string-name>. <article-title>Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus</article-title>. <source>J Diabetes Investig</source>. <year>2013</year>;<volume>4</volume>:<fpage>576</fpage>&#x02013;<lpage>584</lpage>.</mixed-citation></ref><ref id="dom13079-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom13079-cit-0016">
<string-name>
<surname>Kadowaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>K</given-names>
</string-name>. <article-title>Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double&#x02010;blind, placebo&#x02010;controlled study with an open&#x02010;label, long&#x02010;term extension</article-title>. <source>Diabetes Obes Metab</source>. <year>2014</year>;<volume>16</volume>:<fpage>418</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">24205974</pub-id></mixed-citation></ref><ref id="dom13079-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom13079-cit-0017">
<string-name>
<surname>Kadowaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Marubayashi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Yokota</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Katoh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Iijima</surname>
<given-names>H</given-names>
</string-name>. <article-title>Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two phase III clinical studies</article-title>. <source>Expert Opin Pharmacother</source>. <year>2015</year>;<volume>16</volume>:<fpage>971</fpage>&#x02013;<lpage>981</lpage>.<pub-id pub-id-type="pmid">25861982</pub-id></mixed-citation></ref><ref id="dom13079-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom13079-cit-0018">
<string-name>
<surname>Tanaka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takano</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Iijima</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Factors affecting canagliflozin&#x02010;induced transient urine volume increase in patients with type 2 diabetes mellitus</article-title>. <source>Adv Ther</source>. <year>2017</year>;<volume>34</volume>:<fpage>436</fpage>&#x02013;<lpage>451</lpage>.<pub-id pub-id-type="pmid">27981497</pub-id></mixed-citation></ref><ref id="dom13079-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom13079-cit-0019">
<string-name>
<surname>Kadowaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>K</given-names>
</string-name>. <article-title>Efficacy, safety and dose&#x02010;response relationship of teneligliptin, a dipeptidyl peptidase&#x02010;4 inhibitor, in Japanese patients with type 2 diabetes mellitus</article-title>. <source>Diabetes Obes Metab</source>. <year>2013</year>;<volume>15</volume>:<fpage>810</fpage>&#x02013;<lpage>818</lpage>.<pub-id pub-id-type="pmid">23464664</pub-id></mixed-citation></ref><ref id="dom13079-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom13079-cit-0020">
<string-name>
<surname>Park</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Efficacy and safety of dipeptidyl peptidase&#x02010;4 inhibitors in type 2 diabetes: meta&#x02010;analysis</article-title>. <source>Ann Pharmacother</source>. <year>2012</year>;<volume>46</volume>:<fpage>1453</fpage>&#x02013;<lpage>1469</lpage>.<pub-id pub-id-type="pmid">23136353</pub-id></mixed-citation></ref><ref id="dom13079-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom13079-cit-0021">
<string-name>
<surname>Esposito</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cozzolino</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bellastella</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Dipeptidyl peptidase&#x02010;4 inhibitors and HbA1c target of &#x0003c;7% in type 2 diabetes: meta&#x02010;analysis of randomized controlled trials</article-title>. <source>Diabetes Obes Metab</source>. <year>2011</year>;<volume>13</volume>:<fpage>594</fpage>&#x02013;<lpage>603</lpage>.<pub-id pub-id-type="pmid">21320267</pub-id></mixed-citation></ref></ref-list></back></article>